Researchers' Work from Capital Medical University Focuses on Cancer Gene Therapy (Adenovirus vector-mediated herpes simplex virus-thymidine kinase gene/ganciclovir system exhibits anti-tumor effects in an orthotopic hepatocellular carcinoma ...)
By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- Current study results on Biotechnology have been published. According to news reporting originating from Beijing, People's Republic of China, by NewsRx correspondents, research stated, "Adenovirus vector-mediated herpes simplex virus-thymidine kinase/ganciclovir (ADV.tk/GCV) system is a promising approach for cancer gene therapy. This study aimed to investigate the anti-tumor efficacy and the underlying mechanisms of ADV.tk/GCV system in orthotopic hepatocellular carcinoma (HCC) model."
Our news editors obtained a quote from the research from Capital Medical University, "A total of 132 female nude mice orthotopic HCC models were established and tumors were directly injected with ADV.tk (5.0 x 10(6) vector particles/kg) or saline solution, 24 h later the animals were intraperitoneally administrated by ganciclovir (30 mg/kg) or saline solution for 7 consecutive days. We observed that ADV.tk/GCV resulted in a significant regression of tumor growth and a significant prolongation of survival of the mice. At each given time point, the percentages of cleaved caspae-3, caspase-9 and TUNEL positive cells were significantly higher in the ADV.tk + GCV group than saline group (P < 0.005), while CD31 and VEGF staining were significantly less in ADV.tk + GCV group than in saline group (P < 0.005)."
According to the news editors, the research concluded: "In summary, ADV.tk/GCV system exhibits dramatic anti-tumor effects in orthotopic hepatocellular carcinoma model by promoting apoptosis and inhibiting angiogenesis, and is a promising treatment strategy for hepatic carcinoma."
For more information on this research see: Adenovirus vector-mediated herpes simplex virus-thymidine kinase gene/ganciclovir system exhibits anti-tumor effects in an orthotopic hepatocellular carcinoma model. Pharmazie, 2014;69(7):547-552. Pharmazie can be contacted at: Govi-Verlag Pharmazeutischer Verlag Gmbh, Pharmazeutisccarl Mannich Str 26, D-65760 Eschborn, Germany. (Wiley-Blackwell - www.wiley.com/; Pharmazie - onlinelibrary.wiley.com/journal/10.1002/(ISSN)1615-1003)
The news editors report that additional information may be obtained by contacting R.D. Zhu, Capital Med Univ, YouAn Hosp, Dept. of Clin Pathol, Beijing 100069, People's Republic of China. Additional authors for this research include D.X. Chen, D.D. Lin, F.D. Lu, J.M. Yin and N. Li (see also Biotechnology).
Keywords for this news article include: Asia, Biotechnology, Beijing, Oncology, Proteins, Adenovirus, Proteomics, DNA Viruses, Thymidine Kinase, Cancer Gene Therapy, Viral Skin Diseases, DNA Virus Infections, Herpes Simplex Virus, Enzymes and Coenzymes, Hepatocellular Carcinoma, Herpesviridae Infections, People's Republic of China
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC